BB Biotech (BION.SW) Stock Price
BB Biotech Price
BB Biotech (BION.SW) Stock | ISIN CH0038389992 | WKN A0NFN3. The current BB Biotech stock price is 42 CHF (2026). Revenue is 156.11 M CHF. Net income is 196.03 M CHF. The P/E ratio is 11.75. Market capitalization is 2.3 B CHF. BB Biotech operates in the — sector.
BB Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BB Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BB Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BB Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BB Biotech Price |
|---|
BB Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BB Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B CHF) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B CHF) |
| NET INCOME (B CHF) |
| NET INCOME GROWTH (%) |
| DIVIDEND (CHF)DIV. (CHF) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|
| 0.74 | -0.34 | 0 | 0 | 0.11 | 0.29 | 0.16 | 0.17 |
| 1.79 | -146.29 | -100.29 | – | – | 161.61 | -46.76 | 11.54 |
| 99.87 | 100.29 | 10,700 | – | 95.54 | 36.52 | 68.59 | 61.49 |
| 0.74 | -0.34 | 0.11 | -0.01 | 0.11 | 0.11 | 0.11 | 0.11 |
| 0.69 | -0.4 | -0.36 | -0.21 | 0.08 | 0.32 | 0.2 | 0.2 |
| 2.07 | -158.47 | -11.63 | -42.3 | -136.41 | 332 | -39.51 | 2.55 |
| 3.4 | 3.6 | 3.85 | 2.85 | 2 | 3.83 | 4.5 | 0.94 |
| 11.48 | 5.88 | 6.94 | -25.97 | -29.82 | 91.5 | 17.49 | -79.11 |
| 55.39 | 55.36 | 55.01 | 54.85 | 54.83 | 54.83 | 54.83 | 54.83 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BB Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BB Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BB Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BB Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BB Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BB Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BB Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BB Biotech business model & stock analysis
BB Biotech SWOT Analysis
Strengths
- Strong market position with a diversified portfolio of healthcare and biotechnology companies.
- Experienced and knowledgeable management team with a successful track record in the industry.
- Access to a wide range of investment opportunities in the healthcare sector.
Weaknesses
- Vulnerability to changes in regulations and policies affecting the healthcare and biotech industries.
- Dependency on the performance and success of its portfolio companies.
- Limited ability to influence the strategic decisions of its portfolio companies.
Opportunities
- Growing demand for innovative healthcare solutions and advancements in biotechnology.
- Potential for significant returns on investments in high-growth companies in the healthcare sector.
- Possibility of strategic partnerships and collaborations in the industry.
Threats
- Intense competition within the healthcare and biotechnology sectors.
- Economic downturns and market volatility affecting investor sentiment.
- Risks associated with clinical trial failures and regulatory challenges.
BB Biotech Eulerpool Fair Value
BB Biotech historical P/E ratio, EBIT multiple, and P/S ratio
BB Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BB Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BB Biotech Dividend History
17 years of dividend payments
BB Biotech dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
BB Biotech dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the BB Biotech stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
BB Biotech shareholder structure
| % | Name |
|---|---|
4.40108% | |
1.94502% | |
0.91852% | |
0.54713% | |
0.33998% | |
0.31422% | |
0.28889% | |
0.26082% | |
0.20998% | |
0.17674% |
BB Biotech Executives and Management Board
Dr. Thomas Von Planta
(64)Independent Chairman of the Board
Dr. Clive Meanwell
(68)Independent Vice Chairman of the Board · since 2004
Ms. Laura Hamill
(61)Independent Director
Dr. Pearl Huang
(68)Independent Director
Prof. Dr. Mads Thomsen
(65)Independent Director
BB Biotech Supply Chain
Frequently asked questions about BB Biotech
BB Biotech AG is a biotechnology investment company headquartered in Switzerland. The company primarily focuses on investing in a portfolio of innovative and promising biotechnology companies, with a particular emphasis on companies developing and commercializing breakthrough therapies. BB Biotech AG aims to support and generate long-term value by investing in cutting-edge biotech companies that address unmet medical needs and have strong growth potential. By leveraging their extensive expertise and network within the biotech industry, BB Biotech AG aims to provide investors with an attractive investment opportunity in the rapidly evolving field of biotechnology.
BB Biotech stock
BB Biotech Peer Group
BB Biotech Ticker
BB Biotech FIGI
All fundamentals and in-depth analysis of BB Biotech
Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.